$ 188.33
Key Takeaways
Risk factor
High price volatility
Profitability factor
Very low or no dividends
About
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITDA,
Target Price
The average target price of KRYS is 200 and suggests 6% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
